FIT Biotech Oy 

Company release 23.5.2018 at 9.30 EET

FIT Biotech files two international patent applications

FIT Biotech Oy ("company", FITBIO:FN Finland) has filed two international patent applications. These applications are of strategic importance as the company continues to work towards the commercialization of its technology and therapeutic candidates.

The first international patent application covers improved vector technology platforms. The second for the use of the company's technology for the treatment of cancer.

CEO Erkki Pekkarinen comments: "We continue to develop the technology in order to bring better, safer and more cost-effective therapeutics to the market. These patent applications are particularly important for us as we work towards commercializing our gene-based therapies. The biological therapeutics market continues to grow at an unprecedented pace and we are well positioned to meet the demand."

Board of Directors

For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech

FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

Nasdaq Helsinki
Principal media